Table 1

Patient characteristics of the included pSS patients (n = 41)

CharacteristicsValues
Age, years, mean (s.d.)50.4 (13.6)
Female, n (%)40 (97.6)
ACR-EULAR items, n (%)
 Anti-SSA antibodies37 (90.2)
 FS ≥1, parotid gland25 (61.0)
 UWSF ≤0.1 ml/mina27 (65.9)
 Schirmer’s test ≤5 mm/5 min32 (78.0)
 OSS ≥5a23 (56.1)
 SGUS ≥15b25 (61.0)
Parotid histology
 FS, median (IQR)1.1 (0.4–2.3)
 CD45+ infiltrate, %, median (IQR)5.3 (2.2–18.9)
 Fat, %, median (IQR)37.9 (24.2–45.8)
 Fibrosis, %, median (IQR)19.8 (6.8–26.1)
 Presence of lymphoepithelial lesions, n (%)20 (48.8)
 ≤70% IgA plasma cells, n (%)15 (36.6)
 Presence of germinal centres, n (%)14 (34.1)
Parotid saliva (biopsy side), median (IQR)
 UPF, ml/min0.00 (0.00–0.03)
 SPF, ml/min0.06 (0.02–0.11)
Parotid ultrasonography (biopsy side), median (IQR)
 PGUS total score (range 0–13)4.0 (2.0–7.5)
 PGUS-homogeneity (range 0–3)1.0 (0.0–2.0)
 PGUS-hypo (range 0–3)1.0 (1.0–3.0)
 PGUS-hyper (range 0–3)1.0 (1.0–1.0)
CharacteristicsValues
Age, years, mean (s.d.)50.4 (13.6)
Female, n (%)40 (97.6)
ACR-EULAR items, n (%)
 Anti-SSA antibodies37 (90.2)
 FS ≥1, parotid gland25 (61.0)
 UWSF ≤0.1 ml/mina27 (65.9)
 Schirmer’s test ≤5 mm/5 min32 (78.0)
 OSS ≥5a23 (56.1)
 SGUS ≥15b25 (61.0)
Parotid histology
 FS, median (IQR)1.1 (0.4–2.3)
 CD45+ infiltrate, %, median (IQR)5.3 (2.2–18.9)
 Fat, %, median (IQR)37.9 (24.2–45.8)
 Fibrosis, %, median (IQR)19.8 (6.8–26.1)
 Presence of lymphoepithelial lesions, n (%)20 (48.8)
 ≤70% IgA plasma cells, n (%)15 (36.6)
 Presence of germinal centres, n (%)14 (34.1)
Parotid saliva (biopsy side), median (IQR)
 UPF, ml/min0.00 (0.00–0.03)
 SPF, ml/min0.06 (0.02–0.11)
Parotid ultrasonography (biopsy side), median (IQR)
 PGUS total score (range 0–13)4.0 (2.0–7.5)
 PGUS-homogeneity (range 0–3)1.0 (0.0–2.0)
 PGUS-hypo (range 0–3)1.0 (1.0–3.0)
 PGUS-hyper (range 0–3)1.0 (1.0–1.0)
a

<5% missing data. bSGUS is not (yet) included in the ACR-EULAR criteria, but a score of ≥15 has been proposed.

OSS: ocular staining score.

Table 1

Patient characteristics of the included pSS patients (n = 41)

CharacteristicsValues
Age, years, mean (s.d.)50.4 (13.6)
Female, n (%)40 (97.6)
ACR-EULAR items, n (%)
 Anti-SSA antibodies37 (90.2)
 FS ≥1, parotid gland25 (61.0)
 UWSF ≤0.1 ml/mina27 (65.9)
 Schirmer’s test ≤5 mm/5 min32 (78.0)
 OSS ≥5a23 (56.1)
 SGUS ≥15b25 (61.0)
Parotid histology
 FS, median (IQR)1.1 (0.4–2.3)
 CD45+ infiltrate, %, median (IQR)5.3 (2.2–18.9)
 Fat, %, median (IQR)37.9 (24.2–45.8)
 Fibrosis, %, median (IQR)19.8 (6.8–26.1)
 Presence of lymphoepithelial lesions, n (%)20 (48.8)
 ≤70% IgA plasma cells, n (%)15 (36.6)
 Presence of germinal centres, n (%)14 (34.1)
Parotid saliva (biopsy side), median (IQR)
 UPF, ml/min0.00 (0.00–0.03)
 SPF, ml/min0.06 (0.02–0.11)
Parotid ultrasonography (biopsy side), median (IQR)
 PGUS total score (range 0–13)4.0 (2.0–7.5)
 PGUS-homogeneity (range 0–3)1.0 (0.0–2.0)
 PGUS-hypo (range 0–3)1.0 (1.0–3.0)
 PGUS-hyper (range 0–3)1.0 (1.0–1.0)
CharacteristicsValues
Age, years, mean (s.d.)50.4 (13.6)
Female, n (%)40 (97.6)
ACR-EULAR items, n (%)
 Anti-SSA antibodies37 (90.2)
 FS ≥1, parotid gland25 (61.0)
 UWSF ≤0.1 ml/mina27 (65.9)
 Schirmer’s test ≤5 mm/5 min32 (78.0)
 OSS ≥5a23 (56.1)
 SGUS ≥15b25 (61.0)
Parotid histology
 FS, median (IQR)1.1 (0.4–2.3)
 CD45+ infiltrate, %, median (IQR)5.3 (2.2–18.9)
 Fat, %, median (IQR)37.9 (24.2–45.8)
 Fibrosis, %, median (IQR)19.8 (6.8–26.1)
 Presence of lymphoepithelial lesions, n (%)20 (48.8)
 ≤70% IgA plasma cells, n (%)15 (36.6)
 Presence of germinal centres, n (%)14 (34.1)
Parotid saliva (biopsy side), median (IQR)
 UPF, ml/min0.00 (0.00–0.03)
 SPF, ml/min0.06 (0.02–0.11)
Parotid ultrasonography (biopsy side), median (IQR)
 PGUS total score (range 0–13)4.0 (2.0–7.5)
 PGUS-homogeneity (range 0–3)1.0 (0.0–2.0)
 PGUS-hypo (range 0–3)1.0 (1.0–3.0)
 PGUS-hyper (range 0–3)1.0 (1.0–1.0)
a

<5% missing data. bSGUS is not (yet) included in the ACR-EULAR criteria, but a score of ≥15 has been proposed.

OSS: ocular staining score.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close